Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05001477 · ClinicalTrials.gov registry record

Customized TULSA-PRO Ablation Registry

A clinical trial of Prostate Cancer and Prostate Adenocarcinoma, sponsored by Profound Medical.

Recruiting
Registry status
1,000
Enrollment target
5
Study locations

NCT05001477 is a study of Prostate Cancer and Prostate Adenocarcinoma that is actively recruiting participants, run by Profound Medical. The registered enrollment target is 1,000 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (65% higher). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05001477, a study of Prostate Cancer and Prostate Adenocarcinoma, is actively recruiting participants, sponsored by Profound Medical.

RECRUITING
Registry status
1,000 participants
Enrollment target
5
Study locations

Study Summary

This patient registry will capture data from patients who have been or who are undergoing the transurethral ultrasound ablation (TULSA) procedure as part of their routine clinical care. The registry will shed light on real-world outcomes of safety and efficacy of the procedure and understand how a patient's quality of life is affected throughout their follow-up and lifetime.

Interventions

  • DEVICE TULSA Procedure

Study Locations (5)

Texas

  • University of Texas Southwestern Medical Center - Dallas
  • Urology Place - San Antonio

California

  • RadNet's Liberty Pacific West Hills Facility - West Hills

Florida

  • Mayo Clinic Jacksonville - Jacksonville

Pennsylvania

  • Wellspan Health - York

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2021-10-27
Est. Completion 2061-10

Sponsor

Profound Medical

4 total trials

What the Registry Record Tells You About NCT05001477

The ClinicalTrials.gov registry entry for NCT05001477 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (65% higher). The listed sponsor is Profound Medical, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which TULSA Procedure is the first listed.

NCT05001477 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, California, Florida.

Frequently Asked Questions

What is clinical trial NCT05001477 about?

NCT05001477 is a clinical study titled "Customized TULSA-PRO Ablation Registry". This patient registry will capture data from patients who have been or who are undergoing the transurethral ultrasound ablation (TULSA) procedure as part of their routine clinical care. The registry will shed light on real-world outcomes of safety and efficacy of the procedure and understand how a p...

What is the current status of trial NCT05001477?

This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2021-10-27. Estimated completion is 2061-10.

What conditions does trial NCT05001477 study?

This clinical trial studies the following conditions: Prostate Cancer, Prostate Adenocarcinoma, Benign Prostatic Hyperplasia.

What interventions are being tested in trial NCT05001477?

The interventions under investigation include: TULSA Procedure (DEVICE).

Who is sponsoring clinical trial NCT05001477?

This trial is sponsored by Profound Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05001477 being conducted?

This trial has 5 study locations across California, Florida, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.